Education Library

Navin Kapur, MD, discusses the latest science underlying reperfusion and unloading and how it led to the STEMI-DTU pilot and pivotal trials.

Kate Kearney, MD, discusses studies and strategies for revascularization in heart failure with reduced ejection fraction.

Gregg Stone, M.D., presents the newly underway PROTECT IV randomized controlled transcatheter heart failure therapy trial at THT 2022.

Mario Iannaccone, MD, discusses his meta-analysis data supporting pre-PCI placement of Impella® for AMI cardiogenic shock.

Alexandra Lansky, MD, discusses a propensity-adjusted population-based analysis of Impella in patients undergoing high-risk PCI from a large-scale claims dataset. 

Navin Kapur, MD, explains the importance of identifying patients with heart failure who can be enrolled in the PROTECT IV trial.

Navin Kapur, MD, discusses clinical evidence to support ‘on-pump’ complex PCI for patients with heart failure.

Gregg Stone, MD, reviews available data—from PROTECT II through PROTECT IV—for use of mechanical circulatory support during high-risk PCI.

Hady Lichaa, MD, discusses an innovative single-access dry-closure technique with iliac artery angioplasty through the ipsilateral sheath.

A study of 21,848 non-emergent, high-risk patients who underwent PCI with PVADs, including Impella® heart pumps, demonstrates the PVAD patients had a lower rate of mortality and complications than patients who underwent PCI with IABPs.

Gregg Stone, MD, and Duane Pinto, MD, host this panel discussion from SCAI 2021 of Protected PCI and diagnosis and treatment of high-risk and complex coronary disease.

Ziad Ali, MD, presents a case study illustrating imaging-guided PCI in the context of high-risk Protected PCI at the CRT 2021 virtual annual symposium. 

Rajan Patel, MD, discusses clinical data supporting Impella® use in Protected PCI and cardiogenic shock at the CRT 2021 virtual annual symposium. 

The PROTECT IV RCT will leverage advancements in technology and best practices learned since the completion of the PROTECT II RCT and the FDA pre-market approval for Impella 2.5® for high-risk PCI. 

This live case highlights high-risk PCI involving a calcified graft lesion treated with orbital atherectomy and stenting with Impella heart pump hemodynamic support.